Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5327-5335

  Mukerji, Reshmi ^a   Mirza, Shaper ^b   Roche, Aoife M ^c   Widener, Rebecca W ^d   Croney, Christina M ^a   Rhee, Dong Kwon ^e   Weiser, Jeffrey N ^c   Szalai, Alexander J ^a,f   Briles, David E ^a,d,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Alabama at Birmingham   (United States)

^e Sungkyunkwan University   (South Korea)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; PHOSPHORYLCHOLINE; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; BINDING SITE; CELL SURFACE; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL PROTEINS; BINDING, COMPETITIVE; C-REACTIVE PROTEIN; COMPLEMENT C3; CULTURE MEDIA; HUMANS; MICE; PHOSPHORYLCHOLINE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE;

EID: 84869752136     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201967     Document Type: Article

References (81)

1. Gray, B. M., and D. M. Musher. 2008. The history of pneumococcal disease. In Pneumococcal Vaccines. G. R. Seiber, K. P. Klugman, and P. H. Makela, eds. ASM Press, Washington, DC, p. 3-18.
2. Fedson, D. S., and D. M. Musher. 2004. Pneumococcal polysaccharide vaccine. In Vaccines. S. A. Plotkin and W. A. Orenstein, eds. W.B. Saunders, Philadelphia, p. 529-588.
3. Bryce, J., C. Boschi-Pinto, K. Shibuya, and R. E. Black; WHO Child Health Epidemiology Reference Group. 2005. WHO estimates of the causes of death in children. Lancet 365: 1147-1152. (Pubitemid 40417564)
4. Frank, M. M., and J. P. Atkinson. 2001. Complement system. In Samter's Immunologic Diseasse. K. F. Austin, M. M. Frank, J. P. Atkinson, and H. Cantor, eds. Lippincott Williams & Wilkins, New York, p. 282-298.
5. Joiner, K., E. Brown, C. Hammer, K.Warren, and M. Frank. 1983. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing. J. Immunol. 130: 845-849. (Pubitemid 13186316)
6. Hyams, C., E. Camberlein, J. M. Cohen, K. Bax, and J. S. Brown. 2010. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect. Immun. 78: 704-715.
7. Yuste, J., S. Ali, S. Sriskandan, C. Hyams, M. Botto, and J. S. Brown. 2006. Roles of the alternative complement pathway and C1q during innate immunity to Streptococcus pyogenes. J. Immunol. 176: 6112-6120.
8. Jarva, H., T. S. Jokiranta, R. Würzner, and S. Meri. 2003. Complement resistance mechanisms of streptococci. Mol. Immunol. 40: 95-107. (Pubitemid 36959820)
9. Briles, D. E., S. K. Hollingshead, J. King, A. Swift, P. A. Braun, M. K. Park, L. M. Ferguson, M. H. Nahm, and G. S. Nabors. 2000. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182: 1694-1701.
10. Croney, C. M., M. T. Coats, M. H. Nahm, D. E. Briles, and M. J. Crain. 2012. PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin. Vaccine Immunol. 19: 891-896.
11. McDaniel, L. S., J. Yother, M. Vijayakumar, L. McGarry, W. R. Guild, and D. E. Briles. 1987. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 165: 381-394. (Pubitemid 17019822)
12. Ren, B., A. J. Szalai, O. Thomas, S. K. Hollingshead, and D. E. Briles. 2003. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect. Immun. 71: 75-85. (Pubitemid 36026006)
13. Hollingshead, S. K., L. Baril, S. Ferro, J. King, P. Coan, and D. E. Briles; Pneumococcal Proteins Epi Study Group. 2006. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J. Med. Microbiol. 55: 215-221. (Pubitemid 43201750)
14. Melin, M. M., S. K. Hollingshead, D. E. Briles, W. P. Hanage, M. Lahdenkari, T. Kaijalainen, T. M. Kilpi, and H. M. Käyhty. 2008. Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in Finland who had acute otitis media or were nasopharyngeal carriers. Clin. Vaccine Immunol. 15: 1555-1563.
15. Vela Coral, M. C., N. Fonseca, E. Castañeda, J. L. Di Fabio, S. K. Hollingshead, and D. E. Briles. 2001. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg. Infect. Dis. 7: 832-836. (Pubitemid 33121589)
16. Nabors, G. S., P. A. Braun, D. J. Herrmann, M. L. Heise, D. J. Pyle, S. Gravenstein, M. Schilling, L. M. Ferguson, S. K. Hollingshead, D. E. Briles, and R. S. Becker. 2000. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18: 1743-1754. (Pubitemid 30122836)
17. Briles, D. E., S. K. Hollingshead, G. S. Nabors, J. C. Paton, and A. Brooks- Walter. 2000. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19(Suppl. 1): S87-S95. (Pubitemid 32121727)
18. Roche, H., B. Ren, L. S. McDaniel, A. Håkansson, and D. E. Briles. 2003. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect. Immun. 71: 4498-4505. (Pubitemid 36919916)
19. Yother, J., and D. E. Briles. 1992. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J. Bacteriol. 174: 601-609.
20. McDaniel, L. S., D. O. McDaniel, S. K. Hollingshead, and D. E. Briles. 1998. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect. Immun. 66: 4748-4754. (Pubitemid 28453077)
21. Senkovich, O., W. J. Cook, S. Mirza, S. K. Hollingshead, I. I. Protasevich, D. E. Briles, and D. Chattopadhyay. 2007. Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism. J. Mol. Biol. 370: 701-713. (Pubitemid 46879775)
22. Rosenow, C., P. Ryan, J. N. Weiser, S. Johnson, P. Fontan, A. Ortqvist, and H. R. Masure. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 25: 819-829. (Pubitemid 27397511)
23. Yother, J., and J. M. White. 1994. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J. Bacteriol. 176: 2976-2985. (Pubitemid 24152944)
24. Yother, J., G. L. Handsome, and D. E. Briles. 1992. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J. Bacteriol. 174: 610-618.
25. Ren, B., J. Li, K. Genschmer, S. K. Hollingshead, and D. E. Briles. 2012. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin. Vaccine Immunol. 19: 1574-1582.
26. Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. USA 99: 16969-16974. (Pubitemid 36034082)
27. Li, J., D. T. Glover, A. J. Szalai, S. K. Hollingshead, and D. E. Briles. 2007. PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect. Immun. 75: 5877-5885. (Pubitemid 350207827)
28. Briles, D. E., R. C. Tart, E. Swiatlo, J. P. Dillard, P. Smith, K. A. Benton, B. A. Ralph, A. Brooks-Walter, M. J. Crain, S. K. Hollingshead, and L. S. McDaniel. 1998. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin. Microbiol. Rev. 11: 645-657. (Pubitemid 28497567)
29. Claus, D. R., A. P. Osmand, and H. Gewurz. 1976. Radioimmunoassay of human C-reactive protein and levels in normal sera. J. Lab. Clin. Med. 87: 120-128.
30. Szalai, A. J., A. Agrawal, T. J. Greenhough, and J. E. Volanakis. 1999. C-reactive protein: structural biology and host defense function. Clin. Chem. Lab. Med. 37: 265-270. (Pubitemid 29209739)
31. Whitehead, A. S., K. Zahedi, M. Rits, R. F. Mortensen, and J. M. Lelias. 1990. Mouse C-reactive protein. Generation of cDNA clones, structural analysis, and induction of mRNA during inflammation. Biochem. J. 266: 283-290. (Pubitemid 20069050)
32. Volanakis, J. E., and M. H. Kaplan. 1971. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136: 612-614.
33. Yuste, J., M. Botto, S. E. Bottoms, and J. S. Brown. 2007. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog. 3: 1208-1219. (Pubitemid 47510274)
34. Volanakis, J. E., and M. H. Kaplan. 1974. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J. Immunol. 113: 9-17.
35. Mold, C., S. Nakayama, T. J. Holzer, H. Gewurz, and T. W. Du Clos. 1981. Creactive protein is protective against Streptococcus pneumoniae infection in mice. J. Exp. Med. 154: 1703-1708. (Pubitemid 12235210)
36. Yother, J., J. E. Volanakis, and D. E. Briles. 1982. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J. Immunol. 128: 2374-2376. (Pubitemid 12086541)
37. Briles, D. E., J. D. King, M. A. Gray, L. S. McDaniel, E. Swiatlo, and K. A. Benton. 1996. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14: 858-867. (Pubitemid 26280926)
38. Avery, O. T., C. M. Macleod, and M. McCarty. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 79: 137-158.
39. Balachandran, P., A. Brooks-Walter, A. Virolainen-Julkunen, S. K. Hollingshead, and D. E. Briles. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70: 2526-2534. (Pubitemid 34408397)
40. Hollingshead, S. K., R. S. Becker, and D. E. Briles. 2000. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 68: 5889-5900.
41. Yu, J., J. Lin, K. H. Kim, W. H. Benjamin, Jr., and M. H. Nahm. 2011. Development of an automated and multiplexed serotyping assay for Streptococcus pneumoniae. Clin. Vaccine Immunol. 18: 1900-1907.
42. Shoemaker, N. B., and W. R. Guild. 1974. Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation. Mol. Gen. Genet. 128: 283-290.
43. Kim, J. O., and J. N. Weiser. 1998. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 177: 368-377. (Pubitemid 28063761)
44. Roche, A. M., S. J. King, and J. N. Weiser. 2007. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect. Immun. 75: 2469-2475. (Pubitemid 46744338)
45. McCool, T. L., and J. N. Weiser. 2004. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect. Immun. 72: 5807-5813. (Pubitemid 39303692)
46. Darrieux, M., A. T. Moreno, D. M. Ferreira, F. C. Pimenta, A. L. de Andrade, A. P. Lopes, L. C. Leite, and E. N. Miyaji. 2008. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J. Med. Microbiol. 57: 273-278. (Pubitemid 351358529)
47. Briles, D. E., M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J. Exp. Med. 153: 694-705. (Pubitemid 11155803)
48. Claflin, J. L., and M. Cubberley. 1980. Clonal nature of the immune response to phosphocholine. VII. Evidence throughout inbred mice for molecular similarities among antibodies bearing the T15 idiotype. J. Immunol. 125: 551-558. (Pubitemid 10045625)
49. Jones, N. R., M. A. Pegues, M. A. McCrory, S. W. Kerr, H. Jiang, R. Sellati, V. Berger, J. Villalona, R. Parikh, M. McFarland, et al. 2011. Collagen-induced arthritis is exacerbated in C-reactive protein-deficient mice. Arthritis Rheum. 63: 2641-2650.
50. McDaniel, L. S., B. A. Ralph, D. O. McDaniel, and D. E. Briles. 1994. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb. Pathog. 17: 323-337.
51. Brooks-Walter, A., D. E. Briles, and S. K. Hollingshead. 1999. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect. Immun. 67: 6533-6542.
52. Goldenberg, H. B., T. L. McCool, and J. N. Weiser. 2004. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J. Infect. Dis. 190: 1254-1263. (Pubitemid 39287751)
53. Magee, A. D., and J. Yother. 2001. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect. Immun. 69: 3755-3761. (Pubitemid 32493294)
54. Roux, K. H., J. M. Kilpatrick, J. E. Volanakis, and J. F. Kearney. 1983. Localization of the phosphocholine-binding sites on C-reactive protein by immunoelectron microscopy. J. Immunol. 131: 2411-2415. (Pubitemid 14227444)
55. Du Clos, T. W., and C. Mold. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors. Curr. Opin. Organ Transplant. In press.
56. Briles, D. E., G. Scott, B. Gray, M. J. Crain, M. Blaese, M. Nahm, V. Scott, and P. Haber. 1987. Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides. J. Infect. Dis. 155: 1307-1314. (Pubitemid 17080510)
57. Virolainen, A., W. Russell, M. J. Crain, S. Rapola, H. Käyhty, and D. E. Briles. 2000. Human antibodies to pneumococcal surface protein A in health and disease. Pediatr. Infect. Dis. J. 19: 134-138. (Pubitemid 30111409)
58. Ren, B., M. A. McCrory, C. Pass, D. C. Bullard, C. M. Ballantyne, Y. Xu, D. E. Briles, and A. J. Szalai. 2004. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J. Immunol. 173: 7506-7512. (Pubitemid 39628191)
59. Ren, B., A. J. Szalai, S. K. Hollingshead, and D. E. Briles. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72: 114-122. (Pubitemid 38018168)
60. Tu, T., R. L. Fulgham, M. A. McCrory, D. E. Briles, and A. J. Szalai. 1999. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67: 4720-4724.
61. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1996. Role of complement in Creactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect. Immun. 64: 4850-4853. (Pubitemid 26357103)
62. Weiser, J. N., N. Pan, K. L. McGowan, D. Musher, A. Martin, and J. Richards. 1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J. Exp. Med. 187: 631-640. (Pubitemid 28093365)
63. Briles, D. E., C. Forman, J. C. Horowitz, J. E. Volanakis, W. H. Benjamin, Jr., L. S. McDaniel, J. Eldridge, and J. Brooks. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57: 1457-1464. (Pubitemid 19114164)
64. Lieberman, R. M., M. Potter, E. B. Mushinski, W. Humphrey, Jr., and S. Rudikoff. 1974. Genetics of a new IgVH (T15 idiotype) marker in the mouse regulating natural antibody to phosphorylcholine. J. Exp. Med. 139: 983-1001.
65. Roche, H., A. Håkansson, S. K. Hollingshead, and D. E. Briles. 2003. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect. Immun. 71: 1033-1041. (Pubitemid 36254282)
66. Daniels, C. C., P. Coan, J. King, J. Hale, K. A. Benton, D. E. Briles, and S. K. Hollingshead. 2010. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect. Immun. 78: 2163-2172.
67. Darrieux, M., E. N. Miyaji, D. M. Ferreira, L. M. Lopes, A. P. Lopes, B. Ren, D. E. Briles, S. K. Hollingshead, and L. C. Leite. 2007. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect. Immun. 75: 5930-5938. (Pubitemid 350207833)
68. Ochs, M. M., W. Bartlett, D. E. Briles, B. Hicks, A. Jurkuvenas, P. Lau, B. Ren, and A. Millar. 2008. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb. Pathog. 44: 204-214. (Pubitemid 351163528)
69. Daniels, C. C., T. C. Briles, S. Mirza, A. P. Håkansson, and D. E. Briles. 2006. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microb. Pathog. 40: 228-233.
70. Mirza, S., L. Wilson, W. H. Benjamin, Jr., J. Novak, S. Barnes, S. K. Hollingshead, and D. E. Briles. 2011. Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin. Infect. Immun. 79: 2440-2450.
71. Shaper, M., S. K. Hollingshead, W. H. Benjamin, Jr., and D. E. Briles. 2004. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect. Immun. 72: 5031-5040. (Pubitemid 39223387)
72. Omtvedt, L. A., T. N. Wien, T. Myran, K. Sletten, and G. Husby. 2004. Serum amyloid P component in mink, a non-glycosylated protein with affinity for phosphorylethanolamine and phosphorylcholine. Amyloid 11: 101-108. (Pubitemid 39232095)
73. Mikolajek, H., S. E.Kolstoe, V. E. Pye, P. Mangione,M.B. Pepys, and S. P. Wood. 2011. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. J. Mol. Recognit. 24: 371-377.
74. Tomasz, A. 1968. Biological consequences of the replacement of choline by ethanolamine in the cell wall of Pneumococcus: chanin formation, loss of transformability, and loss of autolysis. Proc. Natl. Acad. Sci. USA 59: 86-93.
75. Weiser, J. N., J. B. Goldberg, N. Pan, L. Wilson, and M. Virji. 1998. The phosphorylcholine epitope undergoes phase variation on a 43-kilodalton protein in Pseudomonas aeruginosa and on pili of Neisseria meningitidis and Neisseria gonorrhoeae. Infect. Immun. 66: 4263-4267. (Pubitemid 28402700)
76. Allaoui-Attarki, K., S. Pecquet, E. Fattal, S. Trollé, E. Chachaty, P. Couvreur, and A. Andremont. 1997. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-glycolide) microspheres. Infect. Immun. 65: 853-857. (Pubitemid 27087981)
77. Claflin, J. L., J. George, C. Dell, and J. Berry. 1989. Patterns of mutations and selection in antibodies to the phosphocholine-specific determinant in Proteus morganii. J. Immunol. 143: 3054-3063. (Pubitemid 19281860)
78. Lal, R. B., R. S. Paranjape, D. E. Briles, T. B. Nutman, and E. A. Ottesen. 1987. Circulating parasite antigen(s) in lymphatic filariasis: use of monoclonal antibodies to phosphocholine for immunodiagnosis. J. Immunol. 138: 3454-3460. (Pubitemid 17071933)
79. Briles, D. E., C. Forman, S. Hudak, and J. L. Claflin. 1982. Antiphosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J. Exp. Med. 156: 1177-1185. (Pubitemid 12036279)
80. Cundell, D. R., N. P. Gerard, C. Gerard, I. Idanpaan-Heikkila, and E. I. Tuomanen. 1995. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377: 435-438.
81. Perlmutter, R. M., S. T. Crews, R. Douglas, G. Sorensen, N. Johnson, N. Nivera, P. J. Gearhart, and L. Hood. 1984. The generation of diversity in phosphorylcholine-binding antibodies. Adv. Immunol. 35: 1-37. (Pubitemid 14097635)